aminoimidazole carboxamide has been researched along with gefitinib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chang, CY; Chen, CJ; Chen, WY; Huang, HY; Kuan, YH; Li, JR; Ou, YC; Pan, PH; Wu, CC | 1 |
Chen, X; Gotoh, N; Horike, SI; Igarashi, K; Kato, K; Kita, K; Kohno, S; Meguro-Horike, M; Mukaida, N; Murayama, T; Nakata, A; Nishi, K; Nishimura, T; Saitoh, K; Sasaki, S; Soga, T; Takahashi, C; Tojo, A; Yano, S | 1 |
2 other study(ies) available for aminoimidazole carboxamide and gefitinib
Article | Year |
---|---|
Autophagy contributes to gefitinib-induced glioma cell growth inhibition.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis Regulatory Proteins; Autophagy; Cell Line, Tumor; Gefitinib; Glioma; Growth Inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
Topics: Aminohydrolases; Aminoimidazole Carboxamide; beta Catenin; Carcinogenesis; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Folic Acid; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Methylenetetrahydrofolate Dehydrogenase (NADP); Mitochondria; Multifunctional Enzymes; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Purines; Ribonucleotides | 2019 |